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2 Possible Involvement of the Cacna1e Gene in Migraine: A
3 Search for Single Nucleotide Polymorphism in Different
4 Clinical Phenotypes
5 A. AmbrosiniAQ5 , MD, PhD*; M. D’Onofrio, MD, PhD*; M.G. Buzzi, MD, PhD; I. Arisi, PhD;
6 G.S. Grieco, PhD; F. Pierelli, MD; F.M. Santorelli, MD, PhD; J. SchoenenAQ2 , MD, PhD
7 Objective.—To search for differences in prevalence of a CACNA1E variant between migraine without aura, various
8 phenotypes of migraine with aura, and healthy controls.
9 Background.—Familial Hemiplegic Migraine type 1 (FHM1) is associated with mutations in the CACNA1A gene cod-
10 ing for the alpha 1A (Cav2.1) pore-forming subunit of P/Q voltage-dependent Ca
21 channels. These mutations are not
11 found in the common forms of migraine with or without aura. The alpha 1E subunit (Cav2.3) is the counterpart of Cav2.1
12 in R-type Ca21 channels, has different functional properties, and is encoded by the CACNA1E gene.
13 Methods.—First, we performed a total exon sequencing of the CACNA1E gene in three probands selected because
14 they had no abnormalities in the three FHM genes. In a patient suffering from basilar-type migraine, we identified a single
15 nucleotide polymorphism (SNP) in exon 20 of the CACNA1E gene (Asp859Glu – rs35737760; Minor Allele Frequency
16 0.2241) hitherto not studied in migraine. In a second step, we determined its occurrence in four groups by direct sequencing
17 on blood genomic DNA: migraine patients without aura (N5 24), with typical aura (N5 55), complex neurological auras
18 (N5 19; hemiplegic aura: N5 15; brain stem aura: N5 4), and healthy controls (N5 102).
19 Results.—The Asp859Glu – rs35737760 SNP of the CACNA1E gene was present in 12.7% of control subjects and in
20 20.4% of the total migraine group. In the migraine group it was significantly over-represented in patients with complex
21 neurological auras (42.1%), OR 4.98 (95% CI: 1.69-14.67, uncorrected P5 .005, Bonferroni P5 .030, 2-tailed Fisher’s exact
22 test). There was no significant difference between migraine with typical aura (10.9%) and controls.
23 Conclusions.—We identified a polymorphism in exon 20 of the CACNA1E gene (Asp859Glu – rs35737760) that is
24 more prevalent in hemiplegic and brain stem aura migraine. This missense variant causes a change from aspartate to gluta-
25 mate at position 859 of the Cav2.3 protein and might modulate the function of R-type Ca
21 channels. It could thus be rele-
26 vant for migraine with complex neurological aura, although this remains to be proven.
27 Key words: migraine, migraine aura, genetics, Cav2.3 channels
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29 INTRODUCTION
30 Migraine is a frequent disorder, characterized by
31 headache attacks that may be preceded or accompa-
32 nied by neurological symptoms in about 30% of
33 patients.1 These include visual, sensory, and motor
34 disturbances and are globally defined as “migraine
35 auras.” In the International Classification of Head-
36 ache Disorders-3 beta2 migraine with aura is subdi-
37 vided into nine subtypes, according to the presence
38 or not of headache and the clinical features of the
39 aura, in particular the presence of motor or basilar-
40 type symptoms and the familial occurrence of the
41 disease. Migraine is known to run in families and
42 great efforts have been made in the last two decades
43 to identify its genetic determinants.
44 At present the only monogenic forms of
45 migraine with functionally relevant mutations in a
46 single gene are Familial Hemiplegic Migraine
47 (FHM),3-5 Sporadic Hemiplegic Migraine (SHM),6-8
48 and Migraine with Brainstem aura (BM).9,10 These
49 are phenotypically similar subtypes of migraine with
50 aura, differentiated by familial occurrence or not,
51 the presence of a unilateral motor deficit or of symp-
52 toms attributable to brain stem dysfunction.2
53 Familial Hemiplegic Migraine type 1 (FHM1)
54 (ICHD-3beta 1.2.3.1.1), as well as some cases of
55 SHM (1.2.3.2)6-8 and BM (1.2.2),9 are caused by
56 mutations in the CACNA1A gene (Chr 19p13),
57 coding for the alpha 1A (Cav2.1) pore-forming sub-
58 unit of P/Q voltage-dependent Ca21 channels.
59 Mutations in the ATP1A2 gene (Chr 1q23),
60 coding for the main subunit of the Na/K ATPase
61 pump have been found in FHM2,4 SHM2,6,8 and
62 BM.10 FHM has also been associated with muta-
63 tions on the SCN1A gene (Chr 2q24), coding for
64 the a1 subunit of the neuronal NaV1.1 sodium chan-
65 nel (FHM3).5 However, some FHM families do not
66bear mutations on these genes, so that other FHM
67genes are to be expected. The FHM mutations are
68not found in the common forms of migraine with or
69without aura.
70Linkage analyses and particularly genome-wide
71association studies have identified multiple suscepti-
72bility loci as single nucleotide polymorphisms
73(SNPs).11,12
74A locus on chromosome 1 (1q31) was initially
75found to be associated with FHM13 and later with
76the common migraine types with and without
77aura.14 This locus contains the CACNA1E gene,
78coding for the alpha1E subunit of Cav2.3 (R-type)
79Ca21 channels.15 Cav2.3 channels are the counter-
80parts of Cav2.1 (P/Q Ca
21) channels mutated in
81FHM1, have a similar anatomical distribution16 but
82different functional properties. The CACNA1E
83gene could thus be an interesting candidate gene in
84migraine. In fact, SNPs in this gene have already
85been investigated in two large cohorts of migrai-
86neurs and controls.17,18 No significant difference
87was found between patients and controls, but in the
88first study17 only one CACNA1E SNP marker was
89studied compared to four in the second18 and all
90dbSNP markers had a rather high minor allele fre-
91quency ranging from 0.27 to 0.47.
92We decided therefore to explore more exten-
93sively the CACNA1E gene by using different
94markers and by studying various clinical pheno-
95types of migraine with aura. Our aim was to search
96for differences in prevalence of CACNA1E variants
97between migraine phenotypes and healthy controls.
98METHODS
99Patients’ Enrollment.—Patients and healthy con-
100trols were recruited at the Headache Centre of the
101IRCCS Neuromed (Pozzilli, IS, Italy) and the
102Headache Research Unit of the University of Lie`ge
103(Belgium) between 2001 and 2006. All migraineurs
104were out-patients followed in both Headache Cen-
105ters; healthy controls were recruited among the
106medical and administrative staff, as well as students
107and research fellows attending both hospitals. The
108study was conducted in accordance with the Decla-
109ration of Helsinki and approved by the local Ethics
110Committees. Blood sampling (10 mL) from cubital
Conflicts of interests: No conflict
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111 veins, and genetic testing were performed with the
112 written informed consent of the subjects. Non-
113 Caucasian subjects were excluded in order to
114 reduce genetic variability. None of the patients and
115 healthy volunteers had a familial relationship with
116 other participants in the study. The blood samples
117 were collected by the Laboratory of Neuropharma-
118 cology of the IRCCS Neuromed, where the DNA
119 extraction and gene screening was performed.
120 We recruited 98 migraine patients (71 females and
121 27 males) and 102 healthy controls (72 females and 30
122 males). When the first genetic analyses were performed,
123 patients were diagnosed according to ICHD-II criteria19
124 that did not allow a distinction between FHM subtypes.
125 As soon as ICHD3beta2 was published with the subdivi-
126 sion of FHM into three genetically distinct subtypes, we
127 rescreened all FHM and SHM patients for mutations in
128 CACNA1A (FHM1), ATP1A2 (FHM2), and SCN1A
129 (FHM3) genes known up to 2013. Consequently, using
130 ICHD3beta criteria,2 patients were diagnosed as suffer-
131 ing from either:
132  Migraine without aura – MO (code 1.1) N5 24
133 (F5 20; M5 4)
134  Migraine with typical aura with headache –
135 MTA (code 1.2.1.1) N5 55 (F5 39: M5 16)
136  Familial Hemiplegic Migraine, other loci – FHM
137 (code 1.2.3.1.4) N5 4 (F5 2: M5 2)
138  Sporadic Hemiplegic Migraine-SHM (code
139 1.2.3.2) N5 11; (F5 7: M5 4)
140  Migraine with Brainstem Aura-BM (code 1.2.2)
141 N5 4; (F5 3: M5 1)
142143 The latter three groups of patients were glob-
144 ally called migraine with complex neurological aura
145 (MAplus).
146 Mutation Screening.—Genetic testing was per-
147 formed by direct sequencing of blood genomic DNA.
148 In a first step, three probands (2 BM and 1 FHM) with a
149 strong family history were chosen for a total screening
150 of exons in the CACNA1A, ATP1A2, and SCN1A
151 genes. UTRs were not taken into consideration. They
152 underwent a total screening of the CACNA1E gene by
153 sequencing on an ABI PRISM 3700 capillary sequencer
154 (Applied Biosystem, Foster City, CA). We identified a
155 dbSNP rs35737760 (Asp859Glu in exon 20) in one pro-
156 band. The dbSNP rs35737760 has genomic coordinates
157chr1:181732663 in Human Genome version GRCh38/
158hg38; it is located on exon 20 of NM_000721.3 transcript
159and corresponds to variant Asp859Glu. Following the
160identification of the Asp859Glu substitution, we
161extended the study to migraineurs and controls by
162restriction fragment length polymorphism (RFLP)
163analysis. The Asp859Glu polymorphism was analyzed
164by PCR-RFLP analysis, using the restriction endonucle-
165ase FoKI (New England Biolabs). The PCR reactions





171An amplicon of 588 bp was obtained at stan-
172dard PCR conditions (Tm5 628C).
173174Statistical Analyses.—No power analysis was
175made before starting this study, which was aimed to
176recruit as many migraine with aura patients as pos-
177sible. Due to the low prevalence of patients with
178complex auras and the involvement of only two ter-
179tiary headache centers, we were not able to predict
180how many patients we would be able to enroll for
181analyses. The frequencies of (Asp859Glu –
182rs35737760) variations were calculated from the
183observed variation counts. The association of fre-
184quencies to the different migraine subtypes was
185investigated by inserting dichotomized data (wild
186type and mutated) for the analyzed migraine groups
187(controls, MO, MTA, MAPlus) in 2 3 2 contin-
188gency tables for patients and controls. The associa-
189tion between the selected genetic variation and the
190migraine type was analyzed with the 2-tailed Fish-
191er’s exact test using R-Bioconductor package. The
192significance level was set to 0.05. The computed P
193values were corrected for multiple comparisons
194using both the classical Bonferroni procedure to
195control the Family Wise Error Rate (FWER), and
196the Benjamini & Hochberg procedure to control
197for False Discovery Rate (FDR). P values cor-
198rected with both methods are shown in Table T11.
199RESULTS
200We identified a single nucleotide polymorphism
201(variation Asp859Glu – rs35737760) in exon 20 of
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202 the CACNA1E gene, not previously recognized to
203 link to migraine.
204 This variation was found in 12.7% of control
205 subjects and in 20.4% of the total group of
206 migraine patients, a difference that did not reach
207 statistical significance (see Table 1).
208 However, the Asp859Glu variant was signifi-
209 cantly more represented (42.1%) in FHM, SHM,
210 and BM patients – called here MAplus subgroup –
211 than in control subjects, with an odds ratio (OR) of
212 4.98 (95% CI: 1.69-14.67, uncorrected P5 .005,
213 Bonferroni P5 .030, 2-tailed Fisher’s exact test).
214 The prevalence of the polymorphism was larger in
215 the MAplus subgroup than in MTA patients
216(OR5 5.76: 95% CI: 1.3-24.88), which was statisti-
217cally significant (uncorrected P5 .006, Bonferroni
218P5 .034, 2-tailed Fisher’s exact test).
219In migraine without aura (MO), but not in
220migraine with typical aura (MTA), there was a
221slight numerical, but non-significant, overrepresen-
222tation of the Asp859Glu variant compared to con-
223trols (25.0%; OR5 2.28, 95% CI: 0.82-3.76,
224uncorrected P5 .200, Bonferroni P5 1.000, 2-tailed
225Fisher’s exact test).
226DISCUSSION
227We report on a single nucleotide polymorphism
228(SNP) in exon 20 of the CACNA1E gene
Table 1.—Synopsis of Subjects Recruited for CACNA1E Screening and Prevalence of the (Asp859Glu – rs35737760)
























Controls 102 89 13 (12.7%)
MO 24 18 6 (25.0%) 2.28 0.77 6.80 .200 1.000 .300
MTA 55 49 6 (10.9%) 0.84 0.30 2.34 .803 1.000 .803
MAplus 19 11 8 (42.1%) 4.98 1.69 14.67 .005 (*) .030 (*) .017 (*)





MAplus 19 11 8 (42.1%) 5.76 1.43 24.88 .006 (*) .034 (*) .017 (*)
Odds ratios (OR) and their 95% Confidence Intervals (CI) are shown for the comparison of mutated in migraine subtypes vs
controls, and in MAplus vs MTA.
*Statistical significance was assessed by 2-tailed Fisher’s exact test. Both Bonferroni and FDR (Benjamini & Hochberg
procedure) P value corrections were used. A total of 98 migraine patients were analyzed, 20 of them carrying the mutant
allele. This contingency table is divided into: controls (n5 102); MO, Migraine without aura; MTA, Migraine with typical aura;
MAplus, migraine with complex neurological auras (Brainstem aura, Sporadic or Familial Hemiplegic Migraine).
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229 (Asp859Glu – rs35737760) not studied in migraine
230 up to now. This SNP was overrepresented in the
231 subtype of migraine with aura characterized by
232 complex neurological symptoms such as Familial or
233 Sporadic Hemiplegic and Brainstem aura Migraine
234 not associated with mutations in the known FHM
235 genes. The association was statistically significant,
236 but we are aware that our sample size was small
237 and that replication studies are necessary in an
238 independent, and if possible larger, cohort, to con-
239 firm our results. Compared to healthy controls, it
240 tended to be numerically more frequent in migraine
241 without aura patients, but surprisingly had a low
242 prevalence in migraine with typical aura.
243 The CACNA1E gene is composed of 49 exons
244 and encodes the alpha1E subunit of R-type
245 (Cav2.3) Ca
21 channels. The substitution of aspar-
246 tate by glutamic acid in Cav2.3 determined by the
247 rs35737760 variant is likely to produce only minor
248 functional changes that have not yet been studied.
249 Given the functional neuroanatomy of Cav2.3 chan-
250 nels and certain pathophysiological aspects of
251 migraine and its subtypes, one may nonetheless
252 speculate on its possible role in migraine.
253 R-type (Cav2.3) channels have a widespread distri-
254 bution in the nervous system and share many localiza-
255 tions with P/Q channels.20 Currents mediated by Cav2.3
256 are found in most neurons, such as neocortical and stria-
257 tal neurons,21 CA1 neurons,22 dentate granule cells, cer-
258 ebellar granule neurons,23 neurons of the reticular
259 thalamic nucleus,24 and trigeminal ganglion neurons.25
260 Cav2.3 channels also share many functional properties
261 with P/Q (Cav2.1) Ca
21 channels. Interestingly, in a
262 recent study of patients with a post-concussion syn-
263 drome, the CACNA1E SNP was found to be associated
264 with increased balance deficits, which are also common
265 in FHM patients,26 arguing in favor of its functional sig-
266 nificance. We will limit this discussion to four neural
267 phenomena in which a modulation by Cav2.3 channels
268 might be relevant for migraine pathophysiology: (1)
269 cortical spreading depression (CSD); (2) neuromuscular
270 transmission and cerebellar function; (3) thalamocorti-
271 cal rhythms; (4) trigeminal nociception.
272 First, CSD is likely the culprit for the migraine
273 aura. FHM1 CACNA1A mutations facilitate CSD
274 and glutamate release in knock in mice.27 After
275blockade of P/Q-type Ca21 channels CSD cannot
276be induced in wild-type mouse cortical slices. By
277contrast, blockade of R-type Ca21 channels has
278only a minor inhibitory effect on CSD.28 Conse-
279quently, if the Asp859Glu – rs35737760 SNP in
280patients with complex neurological auras changes
281the functional properties of R-type Ca21 channels,
282this change is not likely to have a major effect on
283CSD. However, while P/Q Ca21 channels are semi-
284nal in action potential-induced exocytosis, R-type
285Ca21 channels play a greater role in spontaneous
286glutamate release.29 It remains to be determined
287whether R-type Ca21 channels may favor spread-
288ing depression in subcortical areas30 that are rele-
289vant for aura symptoms in BM.31 Lamotrigine is
290known to inhibit CSD in rat after chronic treat-
291ment32 and to be effective in preventing attacks of
292MTA,33,34 FHM, SHM, and BM.35,36 Interestingly,
293lamotrigine is able to inhibit Cav2.3 (R-type) cal-
294cium currents.37 Whether this contributes to its
295therapeutic effect in migraine with aura remains to
296be proven. Along the same line, topiramate,
297another inhibitor of CSD during long-term treat-
298ment in rats38 with preventive action in both
299migraine with and without aura, was shown to
300depress R-type Ca21 channels in hippocampal
301neurons.39
302Second, we have described subtle abnormali-
303ties in transmission at the neuromuscular junction
304(NMJ) in migraine patients that were confirmed
305by others.40-44 These abnormalities are restricted
306to migraine with aura patients and most pro-
307nounced in patients with prolonged42 and complex
308neurological auras,40,41,43,44 precisely in the present
309study the subgroup of patients with the highest
310prevalence of the Asp859Glu polymorphism. The
311carbonic anhydrase inhibitor acetazolamide that is
312able to normalize the impairment of neuromuscu-
313lar transmission45 inhibits by 30% Cav2.3 currents
314in vitro.46 R-type Cav2.3 Ca
21 channels play a role
315at the neuromuscular junction and can compensate
316for defective acetylcholine release due to mutated
317P/Q Cav2.1 Ca2
1 with a loss of function in totter-
318ing47 and lethargic mice mutants.48 One cannot
319exclude therefore that a dysfunction of R-type
320channels might contribute to the NMJ
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321 abnormalities found in subgroups of MA patients.
322 Another subclinical abnormality reported in
323 migraine patients concerns the vestibulo-cerebellar
324 system. Subtle cerebellar dysfunctions were found
325 with various methods in migraine patients, espe-
326 cially those suffering from MA.49-51 We have
327 shown a positive correlation between abnormal
328 cerebellar tests and abnormal neuromuscular
329 transmission.52 R-type Ca21 channels are present
330 in Purkinje cells, where they play a role in pre-
331 synaptic long-term potentiation.53 If these channels
332 are dysfunctioning, they could contribute to these
333 subclinical cerebellar abnormalities.
334 A third argument favoring a possible role of
335 Cav2.3 channels in migraine pathophysiology is
336 their involvement in activity control of the reticular
337 thalamic nucleus. Thalamo-cortical rhythmicity is
338 altered in Cav2.3(2/2) mice
54 and hence Cav2.3
339 channels are relevant for the control of thalamo-
340 cortical loops. The latter are thought to be malfunc-
341 tioning in migraine and to be responsible for
342 abnormal sensory processing.55 More specifically,
343 thalamocortical dysrhythmia is likely responsible
344 for the most prevalent electrophysiological bio-
345 marker found in migraine between attacks, ie, defi-
346 cient habituation of cortical evoked potentials.
347 Whether subtle abnormalities in Cav2.3 channels
348 may play a role in other disorders associated like
349 migraine with thalamo-cortical dysrhythmia remains
350 to be investigated.
351 Finally, migraine headache is thought to be
352 generated in the trigeminovascular system.56 Tri-
353 geminal nociception is abnormal during and
354 between attacks.57,58 Cav2.3 Ca
21 channels have a
355 role in nociception, since Cav2.3 knockout mice dis-
356 play abnormal responses to somatic (Cav2.32/2 &
357 1/2) and visceral (Cav2.31/2) inflammatory pain
358 suggesting that these channels can control pain
359 behavior through both spinal and supraspinal mech-
360 anisms.59 Of interest for trigeminal nociception is
361 that one of the six known isoforms of Cav2.3 in
362 mammals, Cav2.3E, is mainly represented in noci-
363 ceptive neurons of the trigeminal ganglion.60 The
364 insert II in the I-II loop that characterizes this iso-
365 form is located in exon 20, where the Asp859Glu
366 variant is located. Moreover, zolmitriptan, one of
367the 5HT1B/D agonists effective in acute migraine
368treatment, was reported to inhibit R-type Ca21
369channels in dissociated rat trigeminal neurons.61
370CONCLUSIONS
371Up until now the CACNA1E gene that enco-
372des the main subunit of R-type (Cav2.3) voltage-
373gated calcium channels has received little atten-
374tion in migraine. Given the distribution and func-
375tional roles of Cav2.3 channels, mutations in the
376CACNA1E gene could in theory be responsible
377for some aspects of migraine pathophysiology. We
378report here that a single nucleotide polymorphism
379in this gene leading to the substitution of aspar-
380tate by glutamate in exon 20 is overrepresented in
381patients suffering from migraine with complex
382neurological auras. The functional consequences
383of this substitution are not yet known and proba-
384bly minor, but this polymorphism could interplay
385with other genetic abnormalities to modify ion
386channel function, as previously shown for specific
387CACNA1A polymorphisms in migraine.62 While
388awaiting the results of functional studies, available
389data on the functional neuroanatomy of Cav2.3
390channels set the scene for a possible role in
391spreading depression, neuromuscular transmission
392and cerebellar function, thalamocortical loops,
393and trigeminal nociception, all of which can be
394impaired in migraine and its subtypes. Needless to
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